Revenue Dependence on a Specific Medical Corporation
First written in FY2019. 3 of 6 entries say "Worsened", first in FY2020. Latest entry: FY2025.
CellSource moved to the "Worse" side of this theme in 2021, 2 years before the typical company in this theme (2023).
The whole theme swung hardest in 2017: 12 of 76 companies on the "Worse" side.
39 other companies' latest entry also says "Mitigated".
- FY2025MitigatedAnnual report
「Of consolidated revenue of ¥3,711.455 million in the fiscal year under review, revenue from Medical Corporation Katsuju-kai (hereinafter, “Katsuju-kai”) and the clinics it operates totaled ¥1,355.036 million, or 36.5% of total revenue, indicating a high degree of dependence on Katsuju-kai for the Group's revenue.」
Revenue from Katsuju-kai was ¥1,355.036 million, or 36.5% of total revenue. Dependence declined from 48.4% in the previous fiscal year, while the company continued to develop new customers and deepen relationships with customers other than Katsuju-kai. - FY2023WorsenedAnnual report
「Of total revenue of ¥4,510.544 million in the fiscal year under review, revenue from Medical Corporation Katsuju-kai (hereinafter, “Katsuju-kai”) and the clinics it operates totaled ¥2,184.663 million, or 48.4% of total revenue, indicating a high degree of dependence on Katsuju-kai for our revenue.」
Revenue from Katsuju-kai increased from ¥1,736.525 million to ¥2,184.663 million, while its share of total revenue rose from 40.6% to 48.4%. The policy of developing new customers and deepening relationships with customers other than Katsuju-kai continues. - FY2022MitigatedAnnual report
「Of total revenue of ¥4,273.829 million in the fiscal year under review, revenue from Medical Corporation Katsuju-kai and the clinics it operates totaled ¥1,736.525 million, or 40.6% of total revenue, indicating a high degree of dependence on Katsuju-kai for our revenue.」
Revenue from Katsuju-kai increased from ¥1,378.702 million, or 47.2%, to ¥1,736.525 million, or 40.6%, while its share of total revenue declined. The company continues to develop new customers and deepen relationships with customers other than Katsuju-kai. - FY2021WorsenedAnnual report
「Of total revenue of ¥2,922.232 million in the fiscal year under review, revenue from Medical Corporation Katsuju-kai and the clinics it operates totaled ¥1,378.702 million, or 47.2% of total revenue, indicating a high degree of dependence on Katsuju-kai for our revenue.」
Revenue from Katsuju-kai increased from ¥810.776 million, or 43.7%, to ¥1,378.702 million, or 47.2%, further increasing dependence on a specific medical corporation for revenue. At the same time, the company stated its policy of developing new customers and deepening relationships with customers other than Katsuju-kai. - FY2020WorsenedAnnual report
「Of total revenue of ¥1,855.475 million in the fiscal year under review, revenue from Medical Corporation Katsuju-kai and the clinics it operates totaled ¥810.776 million, or 43.7% of total revenue, indicating a high degree of dependence on Katsuju-kai for our revenue.」
Revenue from Katsuju-kai increased from ¥513.822 million, or 31.9%, to ¥810.776 million, or 43.7%, increasing dependence on a specific medical corporation for revenue. - FY2019First statedAnnual report
「Of total revenue of ¥1,611.587 million in the fiscal year under review, revenue from Medical Corporation Katsuju-kai and the clinics it operates totaled ¥513.822 million, or 31.9% of total revenue, indicating a high degree of dependence on Katsuju-kai for our revenue.」
The company states that deterioration in its relationship with Katsuju-kai or in the medical corporation's operating environment could affect its business performance.